Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement

Joshua M. Stolker, David J. Cohen, Kevin F. Kennedy, Michael J. Pencina, Suzanne V. Arnold, Neal S. Kleiman, John A. Spertus

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background Drug-eluting stents (DES) reduce restenosis but require prolonged antiplatelet therapy, when compared with bare metal stents. Ideally, the patient should be involved in this risk:benefit assessment prior to selecting DES, to maximize the benefits and cost-effectiveness of care, and to improve medication adherence. However, accurate estimation of restenosis risk may require angiographic factors identified at cardiac catheterization. Methods In a large PCI registry, we used logistic regression to identify clinical and angiographic predictors of clinically-driven target lesion revascularization (TLR) over the first year after stent placement. Discrimination c-statistic and integrated discrimination improvement (IDI) were used to calculate the incremental utility of angiographic variables when added to clinical predictors. Results Of 8501 PCI patients, TLR occurred in 4.5%. After adjusting for DES use, clinical TLR predictors were younger age, female sex, diabetes, prior PCI, and prior bypass surgery (model c-statistic 0.630). Angiographic predictors were vein graft PCI, in-stent restenosis lesion, longer stent length, and smaller stent diameter (c-statistic 0.650). After adding angiographic factors to the clinical model, c-statistic improved to 0.680 and the average separation in TLR risk among patients with and without TLR improved by 1% (IDI = 0.010, 95% CI 0.009–0.014), primarily driven by those experiencing TLR (from 5.9% to 6.9% absolute risk). Conclusions Among unselected PCI patients, the incidence of clinically-indicated TLR is <5% at 1-year, and standard clinical variables only moderately discriminate who will and will not experience TLR. Angiographic variables significantly improve TLR risk assessment, suggesting that stent selection may be best performed after coronary anatomy has been delineated. Short summary (for annotated table of contents) Although several recent studies have challenged traditional expectations regarding the duration of dual antiplatelet therapy, current guidelines recommend at least 6 to 12 months of treatment after implantation of a drug eluting stent, with a shorter course for bare metal stents. Stent selection ideally should involve input from the patient receiving these stents, but multiple studies have suggested that angiographic factors – obtained after the patient has received sedation during the diagnostic catheterization – are important predictors of repeat revascularization. In this analysis from a large registry of patients receiving coronary stents, angiographic characteristics were found to significantly improve risk assessment for target lesion revascularization, when added to clinical variables alone.

Original languageEnglish (US)
Pages (from-to)169-176
Number of pages8
JournalCardiovascular Revascularization Medicine
Volume18
Issue number3
DOIs
StatePublished - Apr 1 2017

Keywords

  • Drug-eluting stent
  • Percutaneous coronary intervention
  • Restenosis
  • Risk assessment

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement'. Together they form a unique fingerprint.

Cite this